TELA BIO, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.675 USD | -0.95% |
|
+3.73% | -29.18% |
| 15/04 | TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR | CI |
| 22/03 | Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating | MT |
Evolution of the average Target Price on TELA Bio, Inc.
Price target over the last 5 years
History of analyst recommendation changes
85150a8.xoSOQh9VZolYrI4ApcD-HO_kL2FLexD7TPySOLsY5JQ.lbDUI1pgHLs8zbdY0PS_LIqhSRkCAlG8e7fiYNhbkqb05e8SaBoguDDK6Q~914fd215586aadc951852e46e7457c66
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.72
USD
Average target price
14.6
USD
Spread / Average Target
+209.32%
High Price Target
18
USD
Spread / Highest target
+281.36%
Low Price Target
12
USD
Spread / Lowest Target
+154.24%
Consensus detail
Consensus revision (last 18 months)
Analysts covering TELA Bio, Inc.
| Piper Sandler | |
| JMP Securities |
Trading Rating
Investor Rating
ESG Refinitiv
C-
EPS Revisions
- Stock Market
- Equities
- TELA Stock
- Consensus TELA Bio, Inc.